Identification
NameHyaluronidase (Human Recombinant)
Accession NumberDB06205
TypeBiotech
GroupsApproved
Description

A purified preparation of the enzyme recombinant human hyaluronidase. Hyaluronidase (Human Recombinant) is produced by genetically engineered Chinese Hamster Ovary (CHO) cells containing a DNA plasmid encoding for a soluble fragment of human hyaluronidase (PH20). The purified hyaluronidase glycoprotein contains 447 amino acids with an approximate molecular weight of 61,000 Daltons.

Protein structureNo structure small
Related Articles
Protein chemical formulaNot Available
Protein average weight61000.0 Da
SequencesNot Available
Synonyms
Hyaluronidase human recombinant
Hyaluronidase recombinant human
Hyaluronidase, human
Recombinant human hyaluronidase
Vorhyaluronidase alfa
External IDs rHuPH20
Product Ingredients Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
HYLENEX RecombinantInjection, solution150 [USP'U]/mLSubcutaneousHalozyme, Inc.2005-12-022016-12-31Us
HYLENEX RecombinantInjection, solution150 [USP'U]/mLSubcutaneousHalozyme, Inc.2005-12-02Not applicableUs
HYLENEX RecombinantInjection, solution150 [USP'U]/mLSubcutaneousBaxter Laboratories2005-12-02Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
ChemophaseHalozyme Therapeutics, Inc
Enhanze SCHalozyme Therapeutics, Inc
Brand mixturesNot Available
CategoriesNot Available
UNII743QUY4VD8
CAS number757971-58-7
Pharmacology
Indication

Indicated as an adjuvant to increase the absorption and dispersion of other injected drugs; for hypodermoclysis; and as an adjunct in subcutaneous urography for improving resorption of radiopaque agents.

Structured Indications
Pharmacodynamics

Hyaluronidase hydrolyzes hyaluronic acid and increase diffusion of injected drugs, thus facilitating their absorption. Hyaluronidase is used for enhancing absorption and distribution of other injected drugs.

Mechanism of action

The family of hyaluronidase enzymes hydrolyzes hyaluronic acid (a glucoseaminoglycan) which is a major constituent of the interstitial barrier. Hyaluronidase (Human Recombinant) is a highly purified recombinant human hyluronidase which lowers the viscosity of the interstitial barrier by breaking down hyaluronic acid and is under investigation as a chemoadjuvant to facilitate local interstitial drug delivery as well as increase bioavilability.

TargetKindPharmacological actionActionsOrganismUniProt ID
HyaluronanSmall moleculeyesNot AvailableHumannot applicabledetails
Transforming growth factor beta-1Proteinunknown
inhibitor
HumanP01137 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions Not Available
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General References
  1. Bookbinder LH, Hofer A, Haller MF, Zepeda ML, Keller GA, Lim JE, Edgington TS, Shepard HM, Patton JS, Frost GI: A recombinant human enzyme for enhanced interstitial transport of therapeutics. J Control Release. 2006 Aug 28;114(2):230-41. Epub 2006 Jun 7. [PubMed:16876899 ]
  2. Frost GI: Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration. Expert Opin Drug Deliv. 2007 Jul;4(4):427-40. [PubMed:17683255 ]
  3. Link [Link]
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedTreatmentDiabetes, Diabetes Mellitus Type 11
1CompletedNot AvailableDiabetes Mellitus (DM)1
1CompletedNot AvailableHealthy Volunteers1
1CompletedBasic ScienceDiabetes, Diabetes Mellitus Type 11
1CompletedHealth Services ResearchDiabetes Mellitus (DM)1
1CompletedTreatmentHealthy Volunteers1
1CompletedTreatmentSuperficial Bladder Cancer1
1Unknown StatusNot AvailableHealthy Volunteers1
1Unknown StatusNot AvailableRisk Factors for or a Diagnosis of Osteoporosis1
1, 2TerminatedSupportive CareLymphedema of the extremities / Neoplasms, Malignant1
1, 2Unknown StatusPreventionBladder Cancers1
2CompletedNot AvailableDiabetes, Diabetes Mellitus Type 11
2CompletedNot AvailableHereditary Angioedema1
2CompletedNot AvailableType 2 Diabetes Mellitus1
2CompletedPreventionHereditary Angioedema1
2CompletedTreatmentDermatitis, Allergic Contact1
2CompletedTreatmentDiabetes, Diabetes Mellitus Type 12
2CompletedTreatmentType 2 Diabetes Mellitus1
2, 3CompletedTreatmentPrimary Immunodeficiency Disorders1
4CompletedTreatmentDehydration3
4CompletedTreatmentDiabetes, Diabetes Mellitus Type 11
4CompletedTreatmentHealthy Volunteers1
4TerminatedTreatmentDehydration1
4Unknown StatusNot AvailableCardiac Output / Dehydration / Pediatrics1
4Unknown StatusTreatmentDiabetes, Diabetes Mellitus Type 11
4WithdrawnTreatmentDehydration1
Not AvailableNot Yet RecruitingTreatmentMultifocal Motor Neuropathy (MMN)1
Not AvailableRecruitingNot AvailableCongenital Immunodeficiency / Secondary Immune Deficiency1
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Injection, solutionSubcutaneous150 [USP'U]/mL
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US7767429 No2007-09-232027-09-23Us
Properties
StateSolid
Experimental PropertiesNot Available
Taxonomy
DescriptionNot Available
KingdomOrganic Compounds
Super ClassOrganic Acids
ClassCarboxylic Acids and Derivatives
Sub ClassAmino Acids, Peptides, and Analogues
Direct ParentPeptides
Alternative ParentsNot Available
SubstituentsNot Available
Molecular FrameworkNot Available
External DescriptorsNot Available

Targets

Kind
Small molecule
Organism
Human
Pharmacological action
yes
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Type iii transforming growth factor beta receptor binding
Specific Function:
Multifunctional protein that controls proliferation, differentiation and other functions in many cell types. Many cells synthesize TGFB1 and have specific receptors for it. It positively and negatively regulates many other growth factors. It plays an important role in bone remodeling as it is a potent stimulator of osteoblastic bone formation, causing chemotaxis, proliferation and differentiati...
Gene Name:
TGFB1
Uniprot ID:
P01137
Uniprot Name:
Transforming growth factor beta-1
Molecular Weight:
44340.685 Da
References
  1. Chang NS: Hyaluronidase activation of c-Jun N-terminal kinase is necessary for protection of L929 fibrosarcoma cells from staurosporine-mediated cell death. Biochem Biophys Res Commun. 2001 May 4;283(2):278-86. [PubMed:11327694 ]
  2. Locci P, Marinucci L, Lilli C, Martinese D, Becchetti E: Transforming growth factor beta 1-hyaluronic acid interaction. Cell Tissue Res. 1995 Aug;281(2):317-24. [PubMed:7648625 ]
  3. Chang NS: Hyaluronidase enhancement of TNF-mediated cell death is reversed by TGF-beta 1. Am J Physiol. 1997 Dec;273(6 Pt 1):C1987-94. [PubMed:9435505 ]
  4. Chang NS: Transforming growth factor-beta protection of cancer cells against tumor necrosis factor cytotoxicity is counteracted by hyaluronidase (review). Int J Mol Med. 1998 Dec;2(6):653-9. [PubMed:9850732 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Toxic substance binding
Specific Function:
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:
ALB
Uniprot ID:
P02768
Uniprot Name:
Serum albumin
Molecular Weight:
69365.94 Da
References
  1. Maingonnat C, Victor R, Bertrand P, Courel MN, Maunoury R, Delpech B: Activation and inhibition of human cancer cell hyaluronidase by proteins. Anal Biochem. 1999 Mar 1;268(1):30-4. [PubMed:10036158 ]
  2. Parameswaran S, Brown LV, Ibbott GS, Lai-Fook SJ: Effect of concentration and hyaluronidase on albumin diffusion across rabbit mesentery. Microcirculation. 1999 Jun;6(2):117-26. [PubMed:10466114 ]
Drug created on March 19, 2008 10:17 / Updated on August 08, 2017 04:48